What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?
https://www.zacks.com/stock/news/2213563/what-s-in-store-for-zimmer-biomet-zbh-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2213563
Jan 22, 2024 - Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.
0
IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?
https://www.zacks.com/stock/news/2217329/idexx-laboratories-idxx-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217329
Jan 29, 2024 - Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.
0
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
https://www.zacks.com/stock/news/2222832/exelixis-exel-q4-earnings-beat-on-lower-r-d-spend-sales-miss?cid=CS-ZC-FT-analyst_blog|earnings_article-2222832
Feb 07, 2024 - Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
0
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
https://www.zacks.com/stock/news/2224881/what-s-in-the-cards-for-medtronic-mdt-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2224881
Feb 12, 2024 - Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.
0
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
https://www.zacks.com/stock/news/2227756/can-rigel-pharmaceuticals-rigl-beat-q4-earnings-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227756
Feb 19, 2024 - Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.
0
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
https://www.zacks.com/stock/news/2228601/sarepta-therapeutics-srpt-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2228601
Feb 20, 2024 - Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2233462/sarepta-therapeutics-srpt-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233462
Feb 28, 2024 - The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
https://www.zacks.com/stock/news/2234137/sarepta-srpt-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2234137
Feb 29, 2024 - Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
0
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
https://www.zacks.com/stock/news/2263473/what-s-in-store-for-puma-biotechnology-pbyi-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2263473
Apr 26, 2024 - On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
0
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2264391/moderna-mrna-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2264391
Apr 29, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
0